Clinical study uncovers interferon signaling and antigen presentation defects in melanoma patients with acquired PD-1 blockade resistance, highlighting mechanisms of tumor immune escape.
In this study, acquired resistance to PD-1 blockade immunotherapy in patients with melanoma was associated with defects in the pathways involved in interferon-receptor signaling and in antigen presentation. (Funded by the National Institutes of Health and others.).
No takes yet. Share an insight, caveat, or question.
Zaretsky et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: